| scholarly article | Q13442814 |
| P50 | author | Hendrik Veelken | Q30513581 |
| Thorsten Zenz | Q46329248 | ||
| Stephan Stilgenbauer | Q47158807 | ||
| P2093 | author name string | Maike Buchner | |
| Christine Dierks | |||
| Hassan Jumaa | |||
| Meike Burger | |||
| Katja Zirlik | |||
| Gabriele Prinz | |||
| Constance Baer | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| P304 | page(s) | 4497-4506 | |
| P577 | publication date | 2010-03-24 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia | |
| P478 | volume | 115 |
| Q36025695 | A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo |
| Q39413689 | A novel retinoblastoma therapy from genomic and epigenetic analyses |
| Q39285533 | A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor |
| Q37866334 | Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets |
| Q37731677 | Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma |
| Q89204598 | An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma |
| Q28257366 | An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia |
| Q42182953 | Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma |
| Q37427684 | Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma |
| Q39045977 | Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells |
| Q38185363 | B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies |
| Q61905852 | B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies |
| Q38124120 | B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. |
| Q40469303 | BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. |
| Q35140116 | BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia |
| Q39056302 | BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity |
| Q28243054 | Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance |
| Q38848633 | CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia |
| Q36115034 | Cell Trafficking in Chronic Lymphocytic Leukemia |
| Q38812974 | Cell adhesion manipulation through single cell assembly for characterization of initial cell-to-cell interaction |
| Q28272891 | Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling |
| Q37774242 | Control systems and decision making for antibody production. |
| Q28484839 | Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 |
| Q38963681 | Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. |
| Q37979306 | Development of novel CXCR4-based therapeutics |
| Q38237648 | Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types? |
| Q37706530 | Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment |
| Q38344404 | Emerging drugs for diffuse large B-cell lymphoma |
| Q36462375 | Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia |
| Q26859114 | Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder |
| Q34613920 | Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. |
| Q35110849 | Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells |
| Q33405080 | Fostamatinib Disodium. |
| Q37576591 | Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. |
| Q53303327 | From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration. |
| Q36782516 | Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib |
| Q26852328 | Ibrutinib (PCI-32765) in chronic lymphocytic leukemia |
| Q47780043 | Ibrutinib and its use in the treatment of chronic lymphocytic leukemia |
| Q38263806 | Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia |
| Q92867679 | Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis |
| Q91867290 | Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients |
| Q36546004 | Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance |
| Q92480194 | Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance |
| Q42198719 | Integrin signaling in cancer cell survival and chemoresistance |
| Q39472188 | Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q28539921 | Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide |
| Q41570171 | Microenvironment-centred dynamics in aggressive B-cell lymphomas |
| Q49196241 | Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia. |
| Q38984569 | Modeling the chronic lymphocytic leukemia microenvironment in vitro |
| Q34020276 | Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy |
| Q39022058 | Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. |
| Q38359004 | New oral small molecules in the treatment of chronic lymphocytic leukemia |
| Q36404778 | Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL |
| Q39027719 | Novel agents in chronic lymphocytic leukemia |
| Q33785941 | PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis |
| Q37655012 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy |
| Q34081881 | Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia |
| Q64073150 | R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells |
| Q36962815 | Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3. |
| Q39610529 | Retinoblastoma tumorigenesis: genetic and epigenetic changes walk hand in hand |
| Q38163044 | Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q37610087 | Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy |
| Q38189089 | Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia |
| Q42221150 | Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration |
| Q54465339 | Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma. |
| Q27026031 | Signal transduction in the chronic leukemias: implications for targeted therapies |
| Q36236545 | Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia |
| Q38296865 | Spleen Tyrosine Kinase Modulates Fibrous Airway Obliteration and Associated Lymphoid Neogenesis After Transplantation |
| Q52621229 | Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. |
| Q30994095 | Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells |
| Q37971736 | Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia |
| Q35423739 | Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas |
| Q42011012 | Syk inhibitors in clinical development for hematological malignancies. |
| Q39164486 | Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder |
| Q92158076 | Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? |
| Q26744277 | Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib |
| Q38012179 | Targeting the B cell receptor pathway in chronic lymphocytic leukemia |
| Q26828782 | Targeting the B-cell receptor signaling pathway in B lymphoid malignancies |
| Q49887906 | Targeting tumour microenvironment by tyrosine kinase inhibitor. |
| Q36163034 | The B-cell receptor signaling pathway as a therapeutic target in CLL. |
| Q36662082 | The SYK tyrosine kinase: a crucial player in diverse biological functions |
| Q37857853 | The Syk kinase as a therapeutic target in leukemia and lymphoma |
| Q37859253 | The bone marrow stroma in hematological neoplasms--a guilty bystander. |
| Q48120395 | The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. |
| Q26865760 | The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy |
| Q26775506 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia |
| Q36172601 | Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo |
| Q64100347 | Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment |
| Q34401328 | Using functional genomics to overcome therapeutic resistance in hematological malignancies. |
| Q34541525 | Viability and stress protection of chronic lymphoid leukemia cells involves overactivation of mitochondrial phosphoSTAT3Ser727. |
| Q35061209 | ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation |
Search more.